



GUJARAT THEMIS BIOSYN LIMITED

REGD. OFFICE & FACTORY : 69/C, GIDC, INDUSTRIAL ESTATE,
VAPI-396 195, DIST. VALSAD, GUJARAT, INDIA.
TEL: 0260-2430027 • FAX : 0260-2100639
Email : hrm@gtbl.co.in
CIN No.: L24230GJ1981PLC004878

GTBL: CS: 2015-16:

15th January, 2016

The General Manager
Dept. of Corporate Services
Bombay Stock Exchange Ltd.
Rotunda Building, 1st Floor,
Mumbai Samachar Marg,
Mumbai - 400 001.

Dear Sir/Madam,

Sub: Audited Financial Results for the half year ended 30th September, 2015.

The Board of Directors at its meeting held today, considered and approved Audited Financial Results for the Half year ended 30th September, 2015, for the purpose of submission of Miscellaneous Application for deregistration of the Company from BIFR as per SICA 1985.

A copy of Audited Financial Results for the half year ended 30th September, 2015 is enclosed for your perusal.

This may be taken as compliance of the Listing Agreement; the Company has entered with your stock exchange.

Kindly acknowledge.

Thanking you,
Yours faithfully,

For **GUJARAT THEMIS BIOSYN LTD.**




Vikas Tarekar
Company Secretary

GUJARAT THEMIS BIOSYN LIMITED

CIN: L24230GJ1981PLC004878

69/C, GIDC Industrial Estate, Vapi - 396 195, Dist. Valsad, Gujarat

Tel: +91 260 2430027 Fax: +91 260 2400639 E-mail: admin@gtbl.co.in Wbsite: www.gtbl.in

Statement of Audited Financial Results for Six Months Ended September 30, 2015

(Rs. in Lacs)

Particulars	Six Months Ended		Year Ended
	30-Sep-15	30-Sep-14	31-Mar-15
	(Audited)	(Unaudited)	(Audited)
1 Income from operations			
(a) Net sales/income from operations (Net of excise duty)	1,651.29	1,549.68	3,144.02
(b) Other operating income	-	-	-
Total income from operations (net)	1,651.29	1,549.68	3,144.02
2 Expenses			
(a) Cost of raw materials consumed	16.44	14.99	28.99
(b) Purchases of stock-in-trade	-	-	-
(c) Changes in inventories of finished goods,work-in-progress and stock-in-trade	-	-	-
(d) Employee benefits expense	215.18	195.39	400.20
(e) Depreciation and amortisation expense	58.87	72.86	137.54
(f) Other expenses			
i) Stores & Spares	91.68	77.99	177.10
ii) Power	657.67	571.94	1,158.45
iii) Fuel	201.88	210.89	410.99
iv) Water	28.04	22.35	46.25
v) Other Expenditure	144.88	130.09	295.25
Total Expenses	1,414.63	1,296.50	2,654.77
3 Profit / (Loss) from operations before other income,finance costs and exceptional items(1-2)	236.66	253.18	489.25
4 Other income	10.22	6.56	8.88
5 Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 + 4)	246.88	259.74	498.13
6 Finance costs	15.61	22.39	38.72
7 Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 - 6)	231.27	237.35	459.41
8 Exceptional items	-	-	-
9 Net Profit from ordinary activities before tax (7 + 8)	231.27	237.35	459.41
10 Tax expense	-	-	-
11 Net Profit from ordinary activities after tax (9 - 10)	231.27	237.35	459.41
12 Extraordinary items (net of tax expense)	-	-	-
13 Net Profit for the period (11 + 12)	231.27	237.35	459.41
14 Paid-up equity share capital Face Value Rs.5/- per share each	726.40	726.40	726.40
15 Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year			(804.93)
16.i Earnings per share (before extraordinary items)- Face Value Rs.5/- per share each (not annualised):			
(a) Basic	1.59	1.63	3.16
(b) Diluted	1.59	1.63	3.16
16.ii Earnings per share (after extraordinary items) Face Value Rs.5/- per share each (not annualised):			
(a) Basic	1.59	1.63	3.16
(b) Diluted	1.59	1.63	3.16

See accompanying notes to Financial Results



GUJARAT THEMIS BIOSYN LIMITED

CIN: L24230GJ1981PLC004878

69/C, GIDC Industrial Estate, Vapi - 396 195, Dist. Valsad, Gujarat

STATEMENT OF ASSETS & LIABILITIES AS AT SEPTEMBER 30, 2015

(Rs. in Lacs)

Particulars	As at	
	30-Sep-15 (Audited)	31-Mar-15 (Audited)
A. EQUITY AND LIABILITIES		
1 Shareholders' Funds		
(a) Share Capital	726.40	726.40
(b) Reserves and Surplus	(573.66)	(804.93)
(c) Money received against share warrants	-	-
Sub-total-Share holders' Funds	152.74	(78.54)
2 Share application money pending allotment	-	-
3 Non-Current Liabilities		
(a) Long-Term Borrowings	491.75	528.35
(b) Deferred Tax Liabilities (Net)	-	-
(c) Other long term liabilities	-	-
(d) Long-Term Provisions	46.63	40.74
Sub-total-Non-current liabilities	538.38	569.09
4 Current Liabilities		
(a) Short-Term Borrowings	115.92	0.00
(b) Trade Payables	568.56	564.61
(c) Other Current Liabilities	242.31	412.54
(d) Short-Term Provisions	4.64	3.55
Sub-total-current liabilities	931.42	980.69
TOTAL - EQUITY AND LIABILITIES	1,622.54	1,471.25
B. ASSETS		
1 Non-Current Assets		
(a) Fixed Assets		
(i) Tangible Assets	967.25	971.36
(ii) Intangible Assets	-	-
(b) Capital Work-In-Progress	2.76	2.76
(c) Non-Current Investments	0.50	0.56
(d) Long-Term Loans And Advances	155.81	130.09
(e) Trade Receivables	-	-
(f) Other Non-Current Assets	17.19	18.97
Sub-total-Non-Current Assets	1,143.51	1,123.74
2 Current Assets		
(a) Current investments -	-	-
(b) Inventories	36.11	33.24
(c) Trade Receivables	372.92	237.15
(d) Cash and Cash Equivalents	31.25	22.93
(e) Short-Term Loans And Advances	38.74	54.15
(f) Other Current Assets	-	0.04
Sub-total-Current Assets	479.03	347.51
TOTAL- ASSETS	1,622.54	1,471.25



	Notes :
1	The above results were reviewed by the Audit Committee and approved by the Board of Directors at its their respective meetings held on January 15, 2016.
2	The Company is mainly engaged in the business of manufacturing Bulk Drugs. Hence, there is no separate reportable segment as per Accounting Standard - 17 (AS-17) "Segment Reporting".
3	In view of carry forward losses / unabsorbed depreciation of earlier years, company being a sick company and relief & concession granted by the BIFR, no provision for the Income Tax has been made on profit of the half year ended September 30, 2015.
4	In respect of Auditor's qualifications / observations in the Audit Report for the year ended 31st March, 2015 that, a) The outstanding balance as at September 30, 2015, in respect of certain balances of trade receivables, deposits, loans & advances, liability for expenses, trade payables and creditors for capital expenditure are subject to confirmation and adjustments necessary upon reconciliation if any, consequential impact thereof in the financial statements is not ascertainable. The Management does not expect any material variation in the financial statements. b) The Company has accumulated losses of Rs. 805.78 lacs leaving Net Worth of the Company of Rs. 152.74 lacs as at September 30, 2015. Further, the Company also has a working capital deficiency. The Company has been registered with the Board for Industrial & Financial Reconstruction (BIFR). Further the Rehabilitation Scheme had been sanctioned by the Board for Industrial and Financial Reconstruction (BIFR) in the hearing held January 12, 2012. The Company has initiated efforts including development of new products and has ventured into manufacturing of goods on own and on job work basis so as to reduce the losses. The Company has made profit for six months period ended September 30, 2015 and previous year 2014-15, 2013-14, 2012-13 & 2011-12. Accordingly, these accounts have been prepared on a going concern basis.
5	The Company is in the process of determining and identifying significant components of fixed assets as prescribed under the provisions of para 4(a) under the heading Notes after Part C in Schedule II of the Companies Act, 2013 and the effect of the same would be taken in due course during the FY 2015-16. Management expects that this would not have a material impact on depreciation on these interim financial statements.
6	The figures of previous period / year have been regrouped / rearranged wherever necessary / practicable to conform to current period presentation.

By order of the Board of Directors
For GUJARAT THEMIS BIOSYN LTD.

Sd/-
Dr. DINESH PATEL
Chairman



Place : Mumbai
Date : January 15, 2016